These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23276549)

  • 1. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis.
    Pariser RJ; Paul J; Hirano S; Torosky C; Smith M
    J Am Acad Dermatol; 2013 May; 68(5):765-73. PubMed ID: 23276549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
    Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
    Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab--a paradoxical effect? A case report.
    Santos G; Sousa LE; João AM
    An Bras Dermatol; 2013; 88(6 Suppl 1):26-8. PubMed ID: 24346872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome.
    Bosch PC
    J Urol; 2014 Jan; 191(1):77-82. PubMed ID: 23792149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
    Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment on 'A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis'.
    Sauder MB; Beecker J; Ramsay T
    J Am Acad Dermatol; 2014 May; 70(5):950-1. PubMed ID: 24742841
    [No Abstract]   [Full Text] [Related]  

  • 7. A response to "Comment on 'A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis'".
    Pariser RJ
    J Am Acad Dermatol; 2014 May; 70(5):951. PubMed ID: 24742842
    [No Abstract]   [Full Text] [Related]  

  • 8. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial.
    Baughman RP; Judson MA; Lower EE; Drent M; Costabel U; Flavin S; Lo KH; Barnathan ES;
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):289-95. PubMed ID: 26847095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab for treatment of cutaneous sarcoidosis.
    Heffernan MP; Smith DI
    Arch Dermatol; 2006 Jan; 142(1):17-9. PubMed ID: 16415380
    [No Abstract]   [Full Text] [Related]  

  • 11. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
    Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
    Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C; Langley RG; Papp K; Tyring SK; Wasel N; Vender R; Unnebrink K; Gupta SR; Valdecantos WC; Bagel J
    Arch Dermatol; 2011 Apr; 147(4):429-36. PubMed ID: 21173304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists.
    Thielen AM; Barde C; Saurat JH; Laffitte E
    Dermatology; 2009; 219(1):59-62. PubMed ID: 19468200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
    Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Gordon KB; Kimball AB; Leonardi CL; Langley RG; Kimel M; Okun M
    J Dermatolog Treat; 2007; 18(6):341-50. PubMed ID: 18058494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P; Van Assche G; Sandborn WJ; Wolf DC; Geboes K; Colombel JF; Reinisch W; ; Kumar A; Lazar A; Camez A; Lomax KG; Pollack PF; D'Haens G
    Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.